Walder Wyss advises BioVersys AG, Basel, a biotech company focusing on research and development of small molecules which switch off drug resistance against antibiotics, on its…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
